RxDoctor Payments Data

Alissa Higinbotham, MD

Neurology · Charlottesville, VANPI 1700382629

Payments from drug & device makers

$37,437in general payments, 2019–2025

Across 79 payments — averaging $473.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Boston Scientific$12K
  • Amneal Pharmaceuticals LLC$1K
  • Supernus Pharmaceuticals, Inc.$306
  • Acorda Therapeutics, Inc$135
  • Biogen$128
  • plus $853 from 17 others

What the payments were for

  • Consulting fees$1,2633%
  • Grants$30,00080%
  • Travel & lodging$3,84310%
  • Food & beverage$2,1826%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,437 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$62,310
Medicare patients
276
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$253,235
Tetrabenazine13$111,824
RytaryCarbidopa/Levodopa46$81,024
NeuproRotigotine13$10,861
Carbidopa-LevodopaCarbidopa/Levodopa311$10,749
Carbidopa-Levodopa ErCarbidopa/Levodopa52$3,130
Carbidopa11$1,473
AmantadineAmantadine Hcl18$1,426
Primidone71$1,195
Propranolol Hcl ErPropranolol Hcl13$1,084
Propranolol Hcl62$989
Quetiapine Fumarate34$851
Gabapentin61$837
Clonazepam45$251
Duloxetine Hcl13$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$1,263$81,02446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 neurology providers in Virginia.

Other neurology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →